Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

for
Cancer, Advanced Cancer, Locally Advanced Carcinoma,
Location: Fairfax VA, Sarasota FL, Nashville TN, St Louis MO,
Sponsor: Angiex, Inc.

Sex: All

Age: 18+

Code: NCT06440005

Phase 1, Recruiting

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

for
Breast Cancer, Breast Cancer Metastatic,
Location: Boston MA, Durham NC, Buffalo NY, Orlando FL,
Sponsor: Incyclix Bio

Sex: All

Age: 18+

Code: NCT05735080

Phase 1, Phase 2, Recruiting
New

Chatbot Utilization for Pedigree Creation and Cancer Risk Assessment in Cancer Genetic Counseling

for
Hereditary Breast Carcinoma, Hereditary Malignant Neoplasm
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT07887620

Recruiting

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

for
Rectal Cancer Stage II, Rectal Cancer Stage III,
Location: Anchorage AK
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 21+

Code: NCT06802172

Recruiting

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

for
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT03604315

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

for
Advanced Solid Tumor, Metastatic Solid Tumor,
Location: New York NY, Jacksonville FL, Cleveland OH,
Sponsor: GI Innovation, Inc.

Sex: All

Age: 18+

Code: NCT05824975

Phase 1, Phase 2, Recruiting

Circulating Tumor DNA Exposure in Peripheral Blood

for
Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer,
Location: Orlando FL, Celebration FL, Centerville OH, Dayton OH
Sponsor: Quantgene Inc.

Sex: All

Age: 18+

Code: NCT03517332

Recruiting

Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment

for
Colorectal Cancer, Breast Cancer, Non Metastatic Cancer
Location: Sherbrooke
Sponsor: Université de Sherbrooke

Sex: All

Age: 40 - 70

Code: NCT06911970

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

for
Solid Tumor, Adult, Metastatic Breast Cancer,
Location: Boston MA, New York NY, Tampa FL, Indianapolis IN,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06625775

Phase 1, Recruiting

Avera Cancer Sequencing and Analytics Protocol (ASAP)

for
Cancer, Cancer Diagnosis, Early Detection of Cancer,
Location: Marshall MN, Sioux Falls SD, Yankton SD, Mitchell SD,
Sponsor: Avera McKennan Hospital & University Health Center

Sex: All

Age: 18+

Code: NCT05142033

Recruiting

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

for
Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma,
Location: Ottawa, Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT02906943

Recruiting

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

for
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant,
Location: Los Angeles CA
Sponsor: VA Greater Los Angeles Healthcare System

Sex: Male

Age: 18+

Code: NCT06706921

Recruiting

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

for
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer,
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT04354064

Recruiting

Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer

for
Cancer, Breast Cancer
Location: Pittsburgh PA
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Sex: Female

Age: 20 - 70+

Code: NCT06858449

Recruiting

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer

for
Malignant Digestive System Neoplasm,
Location: Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06855524

Phase 2, Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

for
Advanced Malignant Solid Neoplasm,
Location: Boston MA, Mineola NY, New York NY, Bethesda MD,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05687136

Phase 1, Recruiting

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

for
Non-small Cell Lung Cancer,
Location: Boston MA, New York NY, New Brunswick NJ, Pittsburgh PA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT05877599

Phase 1, Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: 858 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06395519

Phase 1, Phase 2, Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

for
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer,
Location: Boston MA, New York NY, Madison WI, Aurora CO,
Sponsor: I-Mab Biopharma US Limited

Sex: All

Age: 18+

Code: NCT04900818

Phase 1, Recruiting

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

for
Solid Tumor, Solid Tumor, Adult,
Location: The Bronx NY, New York NY
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 21+

Code: NCT04942717

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial